CAPTRUST Financial Advisors
NWBO

CAPTRUST Financial Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,624
Closed -$11K – 4734
2022
Q2 		$11K Buy
17,624
+11,334
+180% +$7.07K ﹤0.01% 3721
2022
Q1 		$4K Hold
6,290
– – ﹤0.01% 4316
2021
Q4 		$4K Hold
6,290
– – ﹤0.01% 4228
2021
Q3 		$8K Sell
6,290
-1,500
-19% -$1.91K ﹤0.01% 3775
2021
Q2 		$11K Hold
7,790
– – ﹤0.01% 3523
2021
Q1 		$12K Buy
7,790
+2,938
+61% +$4.53K ﹤0.01% 3356
2020
Q4 		$7K Buy
4,852
+190
+4% +$274 ﹤0.01% 2736
2020
Q3 		$3K Buy
4,662
+2,500
+116% +$1.61K ﹤0.01% 2714
2020
Q2 		$1K Buy
+2,162
New +$1K ﹤0.01% 2796
2019
Q4 		– Sell
-6,000
Closed -$1K – 2097
2019
Q3 		$1K Hold
6,000
– – ﹤0.01% 1903
2019
Q2 		$2K Sell
6,000
-3,200
-35% -$1.07K ﹤0.01% 1839
2019
Q1 		$3K Buy
+9,200
New +$3K ﹤0.01% 1666

Other funds holding NWBO

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
ECM
Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return

CAPTRUST Financial Advisors's NWBO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2022, closing a stake of 17,624 shares — an estimated $11K sold.

CAPTRUST Financial Advisors first reported a position in NWBO in Q1 2019 and held it in 12 quarters. The position peaked at $12K in Q1 2021. 13 funds tracked by Wall St. Rank hold NWBO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 17,624 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2022, an estimated $11K.
  • CAPTRUST Financial Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2019 and held it in 12 quarters.
  • CAPTRUST Financial Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $12K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.